Sudarshan Pharma Industries Ltd surged 2% to ₹32.13 per share after acquiring assets of Srujan Lifesciences for ₹25.50 crore. The Telangana facility boosts production of APIs like Ropivacaine, Sitagliptin & Apixaban. With regulatory approvals, SPIL gains faster market entry, stronger supply chain & cost efficiency, enhancing its presence in API & specialty chemicals.